Glow-in-the-Dark dye could help surgeons spot hidden prostate cancer

NCT ID NCT07415135

Not yet recruiting Diagnosis Sponsor: Zhu Yinjie Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a fluorescent dye called DGPR1008 that targets prostate cancer cells. Before robot-assisted prostate removal surgery, 18 men with prostate cancer will receive an injection of the dye. During surgery, a special camera will make cancer cells glow, helping surgeons see and remove them more precisely. The goal is to improve cancer removal and reduce the chance of leaving cancer behind.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DGPR1008 (a fluorescent dye that targets prostate cancer cells)
What this could lead to: If successful, this dye could help surgeons remove more cancer tissue during prostate surgery, potentially reducing the chance of leftover cancer cells.
What could go wrong: This is a small, early-phase study with only 18 participants, so results may not apply to everyone. The dye's effectiveness and safety are still being tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.